Which question this article answers

For knee osteoarthritis, the practical question is usually whether the aim is brief inflammation control or a treatment that may give longer-lasting symptom and function improvement. Corticosteroid injections are mainly used for short-term anti-inflammatory relief, especially when pain is driven by a flare, whereas PRP is considered when the goal is a biologic injection that may help symptoms over a longer period.

That comparison matters because neither option should be presented as proven cartilage restoration. In published trials and reviews, both PRP and steroid injections can reduce pain and improve function, but the balance of benefit may differ with follow-up time, PRP preparation, and platelet dose. Steroid is the more familiar comparator; PRP is the option that sits further along the regenerative side of the spectrum.

Suitability depends on the diagnosis, imaging findings, symptom pattern, previous response to treatment, and the overall condition of the joint. A swollen, inflamed knee with osteoarthritis can point one way; a more chronic pain pattern without active flare may point another. The question here is not “which injection is best for every knee?”, but which approach matches the joint on the scan and the stage of disease.

How PRP and steroid injections differ

PRP is best thought of as a blood-based orthobiologic, not a steroid substitute. It is prepared from the patient’s own blood and concentrates platelets, so the injection is aimed at supporting the joint’s repair processes and altering the local environment inside the knee, rather than simply switching off inflammation. In knee osteoarthritis, trial evidence suggests PRP can improve pain and function, although results vary with preparation method and platelet dose.

By contrast, corticosteroid injection is a powerful anti-inflammatory treatment. Its main job is to calm an irritated joint, particularly when pain is linked to a flare, swelling, or synovitis. The available source material characterises steroid injections as symptom-relieving rather than disease-modifying, which is why they are usually discussed as a short-term control option rather than a joint-support treatment.

That difference in purpose is the practical point. PRP is typically considered when the aim is biologic support and the hope of a more durable symptom response; steroid is chosen when the aim is faster inflammation relief. Both are injections into the knee, but they are not interchangeable, and neither should be described as repairing cartilage in a proven way.

What the evidence suggests about symptom relief

In a patient with knee osteoarthritis, the most useful detail from the newer reviews is not that one injection is “better” in every case, but that the timing of benefit tends to differ. Corticosteroid injection often fits the early part of a painful flare, when swelling and inflammation are the main problems. PRP, by contrast, is more often linked in review-level evidence with improvement that can persist further out in follow-up, which is why it is discussed as a longer-run option in published series.

That said, the picture is not uniform. A 2025 meta-analysis of 18 randomised trials reported better pain and WOMAC outcomes for PRP than placebo, and a separate systematic review of randomised studies found both PRP and corticosteroid injections reduced pain and improved symptoms, with some studies suggesting a longer duration of benefit for PRP. Those findings are encouraging, but they do not translate into a fixed promise for any one knee.

The main reason for caution is that PRP is not one standard product. Trial results vary with platelet concentration, preparation method, dosing schedule, and study design, and another review suggested outcomes may be influenced by higher platelet dose. In practice, that means a clinic can only speak in probabilities: steroid may settle a flare more quickly, while PRP may offer a more sustained symptom response in selected patients, but neither approach gives the same result across all knees or all protocols.

When PRP may be considered

A useful way to think about PRP candidacy is whether the knee pain is coming from ongoing osteoarthritis rather than a short-lived inflammatory episode. In practice, PRP is more often discussed for symptomatic knee osteoarthritis when symptoms have persisted despite simpler measures, and when the aim is to explore a regenerative-leaning option before moving on to more invasive steps. It is not usually framed as a quick fix for an acute swollen flare.

The clinical details matter because not every painful knee behaves the same. Arthritis severity, varus or valgus alignment, meniscal status, body weight, and activity goals all help shape whether an injection-based approach is likely to be worth the effort. A knee with diffuse wear-and-tear change may still be considered for PRP, but the expected room for improvement is different from a knee where pain is driven by a more localised lesion pattern.

That distinction is important because a focal cartilage defect is a different problem from generalized knee osteoarthritis. When symptoms are tied to a discrete defect on imaging, the treatment discussion may move away from PRP alone and towards joint-preservation or scaffold-based repair pathways. By contrast, widespread “bone-on-bone” change tends to narrow the likely benefit from any injection, including PRP, because there is less healthy joint surface left for the treatment to work with.

For a consultation, the practical question is therefore not simply “PRP or not”, but whether the knee looks like persistent osteoarthritis, a focal defect, or end-stage disease. That is the kind of distinction used in advanced cartilage assessment at London Cartilage Clinic on Harley Street, where the next step is usually to match the scan findings to the treatment goal rather than to the diagnosis label alone.

When steroid injection may still be the better fit

A steroid injection still earns its place when the immediate goal is to quiet inflammation quickly, not to pursue a longer-horizon biologic effect. A knee that is hot, swollen and keeping someone awake on 3 or 4 nights in a week, or preventing a planned flight or physiotherapy block, may respond to that short-term anti-inflammatory action in a way that makes the next few days or weeks more manageable.

That is why corticosteroid is usually discussed as a comparator for symptom control rather than as a restoration strategy. It can reduce pain and swelling, but the retrieved source material characterises it as symptom-relieving rather than disease-modifying, so it sits in a different lane from PRP’s orthobiologic framing. In a flare, that difference can matter more than any theory about joint support.

The caution comes with repeated use. A published randomised trial of intra-articular triamcinolone in knee osteoarthritis raised concern about cartilage volume loss over time, which is why steroid is generally used with restraint rather than as a standing long-term plan. That does not make it “never” appropriate; it means the clinical value is strongest when the aim is to bridge a painful episode, settle inflammation before rehabilitation, or help a patient through a defined period of need.

In other words, steroid can be the pragmatic choice for speed, while PRP is being considered for a different reason: the hope of a more sustained symptom response in selected knees.

How to decide what to ask at your appointment

A sensible consultation usually starts with five plain questions: what is the exact diagnosis, is this osteoarthritis or a focal cartilage defect, what does the MRI or X-ray actually show, what is the treatment goal, and what are the realistic alternatives if the first option does not fit? Those answers matter because a short-lived anti-inflammatory injection, a viscosupplement, and a cartilage-focused repair pathway do not serve the same purpose.

Hyaluronic acid is worth naming at that stage because it is aimed at symptom relief and lubrication in symptomatic knee osteoarthritis, not at rebuilding cartilage. ChondroFiller sits in a different category again: it is discussed for selected focal defects, where defect pattern, surrounding cartilage quality, and imaging findings influence suitability more than the diagnosis label alone.

The practical rule is simple. If the main aim is to calm a flare, steroid may still be the more direct tool; if the aim is to look beyond symptom control, the scan needs to show whether there is a repairable focal problem rather than diffuse joint wear. If the imaging suggests the latter, the conversation shifts away from injections that mainly ease pain and towards joint-preservation options that are matched to the defect.

For that reason, the most useful next step is not to ask which injection is “best” in general, but which treatment fits the knee in front of the clinician and why. A specialist review of the imaging at London Cartilage Clinic on Harley Street can help with that assessment.

1. [1] Efficacy and safety of intra-articular platelet-rich plasma (PRP) versus corticosteroid injections in the treatment of knee osteoarthritis: A systematic review of randomized clinical trials. (2025). *Cureus*. https://doi.org/10.7759/cureus.80948 https://doi.org/10.7759/cureus.80948
2. [2] PRP injections for the treatment of knee osteoarthritis: The improvement is clinically significant and influenced by platelet concentration: A meta-analysis of randomized controlled trials. (2025). *The American Journal of Sports Medicine*. https://doi.org/10.1177/03635465241246524 https://doi.org/10.1177/03635465241246524